{"id":"https://openalex.org/W2809521345","doi":"https://doi.org/10.2337/db18-438-p","title":"Liraglutide Effects in Insulin-Treated Patients in LEADER","display_name":"Liraglutide Effects in Insulin-Treated Patients in LEADER","publication_year":2018,"publication_date":"2018-06-22","ids":{"openalex":"https://openalex.org/W2809521345","doi":"https://doi.org/10.2337/db18-438-p","mag":"2809521345"},"language":"en","primary_location":{"id":"doi:10.2337/db18-438-p","doi":"https://doi.org/10.2337/db18-438-p","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db18-438-p","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"CORNELIS TACK","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"CORNELIS TACK","raw_affiliation_strings":["Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081549147","display_name":"Stephan Jacob","orcid":"https://orcid.org/0000-0002-4954-1145","observed_orcids":["https://orcid.org/0000-0002-4954-1145"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"STEPHAN JACOB","raw_affiliation_strings":["Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077027153","display_name":"Cyrus V Desouza","orcid":"https://orcid.org/0000-0001-6660-0568","observed_orcids":["https://orcid.org/0000-0001-6660-0568"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"CYRUS DESOUZA","raw_affiliation_strings":["Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080463002","display_name":"Stephen Charles Bain","orcid":"https://orcid.org/0000-0001-8519-4964","observed_orcids":["https://orcid.org/0000-0001-8519-4964"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"STEPHEN C. BAIN","raw_affiliation_strings":["Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067359287","display_name":"Michael Albrecht Nauck","orcid":"https://orcid.org/0000-0002-5749-6954","observed_orcids":["https://orcid.org/0000-0002-5749-6954","https://orcid.org/0000-0003-2455-0472"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"MICHAEL A. NAUCK","raw_affiliation_strings":["Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077595764","display_name":"John R. Petrie","orcid":"https://orcid.org/0000-0002-4894-9819","observed_orcids":["https://orcid.org/0000-0002-4894-9819"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"JOHN PETRIE","raw_affiliation_strings":["Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072011562","display_name":"Neil R Poulter","orcid":"https://orcid.org/0000-0002-6292-997X","observed_orcids":["https://orcid.org/0000-0002-6292-997X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"NEIL R. POULTER","raw_affiliation_strings":["Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059098934","display_name":"Richard E. Pratley","orcid":"https://orcid.org/0000-0002-2912-1389","observed_orcids":["https://orcid.org/0000-0002-2912-1389"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"RICHARD E. PRATLEY","raw_affiliation_strings":["Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"HELEN VANYA BIERING KJAER STEGMANN","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"HELEN VANYA BIERING KJAER STEGMANN","raw_affiliation_strings":["Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070579413","display_name":"Heidrun Bosch\u2010Traberg","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"HEIDRUN BOSCH-TRABERG","raw_affiliation_strings":["Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018407864","display_name":"Elena Startseva","orcid":"https://orcid.org/0000-0002-9363-7056","observed_orcids":["https://orcid.org/0000-0002-9363-7056"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"ELENA STARTSEVA","raw_affiliation_strings":["Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5090437675","display_name":"Bernard Zinman","orcid":"https://orcid.org/0000-0002-0041-1876","observed_orcids":["https://orcid.org/0000-0002-0041-1876"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"BERNARD ZINMAN","raw_affiliation_strings":["Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nijmegen, Netherlands, Villingen, Germany, Omaha, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, S\u00f8borg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.5561,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.67601545,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"67","issue":"Supplement_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9079999923706055},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9190000295639038},{"id":"https://openalex.org/keywords/insulin-treated-patients","display_name":"insulin-treated patients","score":0.8069999814033508},{"id":"https://openalex.org/keywords/cardiovascular-outcomes","display_name":"cardiovascular outcomes","score":0.5600000023841858},{"id":"https://openalex.org/keywords/major-adverse-cardiovascular-events","display_name":"major adverse cardiovascular events","score":0.8889999985694885},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.8410000205039978},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.9670000076293945},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.8339999914169312},{"id":"https://openalex.org/keywords/body-weight","display_name":"body weight","score":0.7559999823570251},{"id":"https://openalex.org/keywords/systolic-blood-pressure","display_name":"systolic blood pressure","score":0.9139999747276306},{"id":"https://openalex.org/keywords/ldl-cholesterol","display_name":"LDL cholesterol","score":0.9639999866485596},{"id":"https://openalex.org/keywords/leader-trial","display_name":"LEADER trial","score":0.878000020980835},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.35499998927116394},{"id":"https://openalex.org/keywords/cardiovascular-risk-reduction","display_name":"cardiovascular risk reduction","score":0.6570000052452087},{"id":"https://openalex.org/keywords/subgroup-analysis","display_name":"subgroup analysis","score":0.7070000171661377}],"concepts":[{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.9859905242919922},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8181527853012085},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.6908571720123291},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.666160523891449},{"id":"https://openalex.org/C2780668416","wikidata":"https://www.wikidata.org/wiki/Q202758","display_name":"Hypoglycemia","level":3,"score":0.636612594127655},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6297357082366943},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5521388053894043},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5465505123138428},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5425544381141663},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.519605815410614},{"id":"https://openalex.org/C544821477","wikidata":"https://www.wikidata.org/wiki/Q718113","display_name":"Weight loss","level":3,"score":0.5055508613586426},{"id":"https://openalex.org/C2778024521","wikidata":"https://www.wikidata.org/wiki/Q55639806","display_name":"Basal (medicine)","level":3,"score":0.4798828661441803},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.36027276515960693},{"id":"https://openalex.org/C511355011","wikidata":"https://www.wikidata.org/wiki/Q12174","display_name":"Obesity","level":2,"score":0.1778894066810608},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2337/db18-438-p","doi":"https://doi.org/10.2337/db18-438-p","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db18-438-p","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2951955618","https://openalex.org/W2954546034","https://openalex.org/W2129794960","https://openalex.org/W2765475108","https://openalex.org/W4299652385","https://openalex.org/W1826263849","https://openalex.org/W2916549936","https://openalex.org/W2915555967","https://openalex.org/W3125117881","https://openalex.org/W3015694620"],"abstract_inverted_index":{"Combining":[0],"GLP-1":[1],"analogs":[2],"and":[3,31,60,74,109,189,204,263,280,293,353,383,425,451,472,595,657],"insulin":[4,85,88,101,108,116,257],"has":[5],"complementary":[6],"benefits,":[7],"but":[8,131,265],"long-term":[9],"data":[10],"are":[11],"sparse.":[12],"In":[13,144,272],"the":[14,145,222,229,244,251,254,295],"LEADER":[15],"cardiovascular":[16],"(CV)":[17],"outcomes":[18,82],"trial":[19,224],"(N=9340;":[20],"median":[21],"follow-up":[22],"3.8":[23],"years;":[24],"NCT01179048),":[25],"rates":[26],"of":[27,66,568],"major":[28],"CV":[29,58,215,282,302],"events":[30],"hypoglycemia":[32,168,297],"were":[33,62,98,105,112,191,241],"lower":[34],"when":[35],"liraglutide":[36,136,148,220,286],"vs.":[37,89,91,138,151],"placebo":[38,139,152],"was":[39,124,226,248],"added":[40],"to":[41,135,305],"standard":[42],"care":[43],"(frequently":[44],"including":[45],"insulin)":[46],"in":[47,64,166,195,221,228,243,250,261,269,274],"patients":[48,97,133,277,306],"with":[49,114,162,219,259,278,285,299],"type":[50],"2":[51],"diabetes":[52],"(T2D)":[53],"at":[54,122],"high":[55,281],"risk":[56,216,303],"for":[57,193,253],"disease,":[59],"there":[61,190],"improvements":[63],"control":[65],"glycemia,":[67],"body":[68,291],"weight,":[69,264],"systolic":[70],"blood":[71],"pressure":[72],"(SBP)":[73],"lipids.":[75],"This":[76],"post-hoc":[77],"subgroup":[78,231,258],"analysis":[79],"assessed":[80],"these":[81],"by":[83],"baseline":[84,123],"use:":[86],"no":[87,266],"basal-only":[90,107,146,230],"other.":[92],"At":[93],"baseline,":[94],"5171":[95],"(55%)":[96],"not":[99,307],"on":[100,106,308],"treatment,":[102],"3159":[103],"(34%)":[104],"1010":[110],"(11%)":[111],"treated":[113],"other":[115,256,270],"regimens":[117],"(9.7%":[118],"premix).":[119],"Insulin":[120],"use":[121],"balanced":[125],"overall":[126],"between":[127],"randomized":[128,134],"treatment":[129,154,284],"groups,":[130],"fewer":[132],"(29%)":[137],"(43%)":[140],"initiated":[141],"in-trial":[142],"insulin.":[143,309],"subgroup,":[147],"reduced":[149,180,290],"A1C":[150,262],"(estimated":[153,170,232],"difference":[155],"[ETD]:":[156],"\u22120.48%,":[157],"95%":[158,174,185,200,210,236],"CI:":[159,175,186,201,211,237],"\u22120.57;":[160],"\u22120.38),":[161],"a":[163,300],"significant":[164,267],"reduction":[165,217,304],"severe":[167,296],"rate":[169,171],"ratio:":[172,234],"0.42,":[173],"0.26;":[176],"0.68).":[177],"Liraglutide":[178],"also":[179],"weight":[181,292],"(ETD:":[182,197,207],"\u22122.5":[183],"kg,":[184],"\u22123.0;":[187],"\u22122.1)":[188],"trends":[192],"reductions":[194,260],"SBP":[196],"\u22121.1":[198],"mmHg,":[199],"\u22122.4;":[202],"0.1)":[203],"LDL":[205],"cholesterol":[206],"-1.3":[208],"mg/dL,":[209],"-3.6;":[212],"1.0).":[213],"The":[214],"observed":[218],"full":[223],"population":[225],"similar":[227,242,301],"hazard":[233],"0.84,":[235],"0.70;":[238],"1.00).":[239],"Results":[240],"no-insulin":[245],"subgroup.":[246],"There":[247],"heterogeneity":[249],"results":[252],"smaller,":[255],"differences":[268],"endpoints.":[271],"conclusion,":[273],"basal":[275],"insulin-treated":[276],"T2D":[279],"risk,":[283,298],"improved":[287],"glycemic":[288],"control,":[289],"halved":[294],"Disclosure":[310],"C.":[311,386],"Tack:":[312],"Advisory":[313,337,367,401,416,493,540],"Panel;":[314,338,368,402,417,494,541],"Self;":[315,327,331,339,346,357,363,369,374,389,396,403,409,418,444,466,487,495,501,507,511,517,528,542,551,555,565,574,615,620,627,632,639,646],"Merck":[316,397,434,455,474,518,597,663],"Sharp":[317,435,456,475],"&":[318,398,436,457,476,598,664],"Dohme":[319,437,458,477],"Corp.,":[320,438,459,478],"Novo":[321,332,358,364,390,410,439,461,483,496,512,544,557,601,616,621,628,633,640,647],"Nordisk":[322,333,359,365,391,411,440,462,484,497,513,545,558,602,617,622,629,634,641,648],"A/S,":[323,392,546,559,649],"AstraZeneca.":[324,328,413],"Research":[325,394,407,464,515,549],"Support;":[326,395,408,465,516,550],"Speaker's":[329,344,361,372,442,505,553],"Bureau;":[330,345,362,373,443,506,554],"A/S.":[334,360,441,463,485,498,514,618,623,630,635,642],"S.":[335],"Jacob:":[336],"AstraZeneca,":[340,350,419,445,467,543,556,575,654],"Boehringer":[341,347,420,446,502,576,650],"Ingelheim":[342,348,421,447,503,577,651],"GmbH.":[343,504],"GmbH,":[349,422,448],"Eli":[351,423,449,470,593,655],"Lilly":[352,424,450,471,594,656],"Company.":[354],"Board":[355],"Member;":[356],"Foundation.":[366],"MSD":[370,375],"K.K..":[371],"K.K.,":[376],"Menarini":[377],"Group,":[378],"Roche":[379],"Diabetes":[380,529],"Care":[381],"Health":[382],"Digital":[384],"Solutions.":[385],"Desouza:":[387],"Consultant;":[388,486,510,645],"Sanofi.":[393],"Co.,":[399,599,665],"Inc..":[400,509,525,548],"Medscape.":[404],"S.C.":[405],"Bain:":[406],"Inc.,":[412,429,561,579,581,586,589,592,600,603,605,653,661,666],"M.A.":[414],"Nauck:":[415],"Company,":[426,452,473,596,658],"Fractyl":[427],"Laboratories,":[428],"GlaxoSmithKline":[430,481,582],"plc.,":[431,482,583],"Berlin-Chemie":[432,453,468],"AG,":[433,454,469,480,536],"Medscape,":[460],"Novartis":[479],"Nordic":[488],"Bioscience,":[489],"Empros.":[490],"J.":[491],"Petrie:":[492],"Other":[499,526,563,572],"Relationship;":[500,527,564,573],"Pfizer":[508,604],"KGaA,":[519],"Itamar":[520],"Medical":[521],"Ltd.,":[522],"Janssen":[523,584,659],"Pharmaceuticals,":[524,578,585,588,591,652,660],"UK,":[530],"Applied":[531],"Clinical":[532],"Intelligence":[533],"Ltd,":[534],"Bayer":[535],"QuintilesIMS.":[537],"N.R.":[538],"Poulter:":[539],"Amgen":[547,560],"Servier.":[552,562],"International":[566],"Society":[567],"Hypertension.":[569],"R.E.":[570],"Pratley:":[571],"Eisai":[580],"Lexicon":[587],"Ligand":[590],"Sanofi-Aventis,":[606],"Takeda":[607],"Development":[608],"Center":[609],"Americas,":[610],"Inc.":[611],"H.":[612,624],"Stegmann:":[613],"Employee;":[614,626,638],"Stock/Shareholder;":[619,631],"Bosch-Traberg:":[625],"E.":[636],"Startseva:":[637],"B.":[643],"Zinman:":[644],"Sanofi,":[662],"Abbott.":[667]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2}],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2018-06-29T00:00:00"}